Skip to main content
DuChemBio Co, LTD logo

DuChemBio Co, LTD — Investor Relations & Filings

Ticker · 176750 ISIN · KR7176750008 KO Manufacturing
Open in API
Filings indexed 291 across all filing types
Latest filing 2024-12-16 Delisting Announcement
Country KR South Korea
Listing KO 176750

About DuChemBio Co, LTD

http://www.duchembio.com/en/

DuChemBio Co., Ltd. is a pharmaceutical company specializing in the development, manufacturing, and commercialization of radiopharmaceuticals. The company focuses on products for both diagnosis and treatment, with a primary emphasis on positron emission tomography (PET) imaging tracers. Its portfolio targets key therapeutic areas, including oncology for cancer detection and neurology for conditions such as Alzheimer's and Parkinson's disease. The company's mission is to develop novel radiopharmaceuticals and achieve successful commercialization on a global scale.

Recent filings

Filing Released Lang Actions
상장폐지결정 (코스닥시장 이전상장)
Delisting Announcement Classification · 100% confidence The document is an official announcement regarding the delisting of DuChemBio from the KONEX market due to its transfer to the KOSDAQ market. It explicitly uses the header '상장폐지 결정' (Delisting Decision) and provides details on the delisting date, reasons, and future schedule. This fits the definition of a Delisting Announcement (DLST).
2024-12-16 Korean
증권발행실적보고서
Share Issue/Capital Change Classification · 100% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed with the Financial Supervisory Service (FSS) in South Korea. This document details the final results of a public offering, including subscription and allocation data, share issuance details, and the use of proceeds. This type of filing is a standard regulatory requirement following a capital raise and falls under the category of 'Share Issue/Capital Change' (SHA) as it reports the actual issuance of new shares and the resulting capital structure changes.
2024-12-16 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of determining shareholders eligible to attend the 22nd Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of a corporate action (setting a record date). Given the nature of the announcement as a regulatory disclosure regarding shareholder rights and meeting preparation, it fits best under the general regulatory filing category.
2024-12-13 Korean
유상증자또는주식관련사채등의청약결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the results of a public offering (subscription results) for DuChemBio. It details the number of shares subscribed by different investor groups (employee stock ownership, institutional, and general investors) and provides the subscription rate. This falls under the category of share issuance and capital changes, specifically reporting the outcome of a capital-raising event.
2024-12-12 Korean
[발행조건확정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고서' (Securities Registration Statement Amendment) filed with the Financial Services Commission (금융위원회) in South Korea. It details the finalization of the offering price for a public offering of shares (기명식 보통주) for DuChemBio (주식회사 듀켐바이오). This document is a regulatory filing related to capital raising and share issuance, which falls under the 'Share Issue/Capital Change' category.
2024-12-10 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 95% confidence The document is a '투자설명서 정정신고' (Amendment to the Investment Prospectus) filed by DuchemBio. It details corrections made to the previously submitted prospectus, specifically regarding the final offering price and demand forecast results. In the context of financial filings, a prospectus (and its amendments) is a core regulatory document used for public offerings. While it is an amendment, it falls under the category of a prospectus/offering document, which is best classified as a Regulatory Filing (RNS) or a specific offering document. Given the provided categories, 'RNS' serves as the appropriate fallback for this type of regulatory disclosure.
2024-12-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.